Transgene Downplays Impact Of Pexa-Vec Phase III Cancer Trial Failure
A late-phase assessment of the oncolytic virus in liver cancer patients was stopped early for futility but Transgene thinks the failure is an isolated event.
You may also be interested in...
Faced with the risk of losing their investment from a possible stock delisting amid prosecutors’ probes into company’s management, SillaJen’s individual minority shareholders are demanding the Korea Exchange resume trading of the biotech’s stock, in a rare united move.
The South Korean pharma/biotech industry suffered a series of negative blows in 2019 but there were still notable achievements including major drug approvals and large-scale licensing deals.
After a lackluster year so far for South Korean biotech IPOs amid disappointing clinical trial news, investor interest is beginning to pick up, with several companies that have been under the spotlight slated to debut on the market in the coming months.